Cycle-length evidence
Thymalin cycle length: what human studies ran
Not approved — research use onlyBLimited human data
Short answer: there is no established Thymalin cycle length or break. The human studies below ran for set periods under monitoring; none tested repeated courses.
Treatment and follow-up in human studies
What has not been tested
- On-and-off schedules or breaks between courses.
- Repeated courses and long-term exposure beyond the periods listed.
- Thymalin combined with other compounds, unless a study above says so.
Frequently asked questions
Is there an established Thymalin cycle length?
No. Human studies administered Thymalin for the periods listed on this page. Those are study durations; none tested an on-and-off schedule or a break.
What is the longest human study of Thymalin?
The durations are listed on this page with their sources; compare them directly rather than relying on a summary.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
References
- Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells Bull Exp Biol Med. 2020
- Expression features of T-lymphocytes, B-lymphocytes and macrophages in the post-traumatic regenerate of the mandible rats under conditions of filling a bone defect with hydroxyapatite-containing osteotropic material and thymalin injecting the surrounding soft tissues Pol Merkur Lekarski. 2024
- Results and Prospects of Using Activator of Hematopoietic Stem Cell Differentiation in Complex Therapy for Patients with COVID-19 Stem Cell Rev Rep. 2021
- [Morphological compound and indicators of the blood clotting system in severe COVID-19 patients of middle aged and elderly during treatment of Tocilizumab and Thymalin] Adv Gerontol. 2022
- The Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19 Int J Mol Sci. 2023
- [Treatment of secretory otitis media in children, depending on the stage of the process and on the background of the pathological conditions] Georgian Med News. 2019
- Drugs@FDA: FDA-Approved Drugs (search of approved applications) FDA Drugs@FDA / openFDA drug/drugsfda. 2026
- DailyMed label search (structured product labels) NLM DailyMed. 2026
- [Age-related characteristics of the thymus and adrenal cortex function in CBA mice immunized by T-dependent antigen] Fiziol Zh. 2005
- Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line Int J Mol Sci. 2022
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act, updated May 14, 2026 FDA. 2026
- World Anti-Doping Code International Standard: Prohibited List 2026 WADA. 2026
- [HIV infection in servicemen (the work experience of a specialized hospital department)] Voen Med Zh. 1995
- [Effect of thymalin on immunologic reactivity of patients with non-specific lung diseases] Ter Arkh. 1989
- Peptides of pineal gland and thymus prolong human life Neuro Endocrinol Lett. 2003